Gt Biopharma, Inc. GTBP
We take great care to ensure that the data presented and summarized in this overview for GT Biopharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in GTBP
Top Purchases
Top Sells
About GTBP
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Insider Transactions at GTBP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2023
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+18.94%
|
$0
$0.29 P/Share
|
|
Aug 11
2023
|
Manu Ohri CFO & Secretary |
BUY
Other acquisition or disposition
|
Indirect |
200,000
+40.0%
|
$0
$0.29 P/Share
|
|
Aug 11
2023
|
Manu Ohri CFO & Secretary |
SELL
Other acquisition or disposition
|
Direct |
200,000
-100.0%
|
$0
$0.29 P/Share
|
|
Aug 11
2023
|
Manu Ohri CFO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
$0
$0.29 P/Share
|
|
Apr 11
2023
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+7.08%
|
$0
$0.5 P/Share
|
|
Apr 06
2023
|
Manu Ohri CFO & Secretary |
BUY
Open market or private purchase
|
Indirect |
50,000
+50.0%
|
$0
$0.5 P/Share
|
|
Jul 15
2022
|
Manu Ohri CFO & Secretary |
BUY
Other acquisition or disposition
|
Indirect |
100,000
+50.0%
|
-
|
|
Jul 15
2022
|
Manu Ohri CFO & Secretary |
SELL
Other acquisition or disposition
|
Direct |
100,000
-100.0%
|
-
|
|
Jul 15
2022
|
Manu Ohri CFO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Jul 15
2022
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
278,058
+31.44%
|
-
|
|
Feb 25
2021
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Conversion of derivative security
|
Direct |
50,102
+7.07%
|
$150,306
$3.4 P/Share
|
|
Feb 16
2021
|
Gregory Berk Pres. of R&D, CMO |
BUY
Grant, award, or other acquisition
|
Direct |
278,058
+50.0%
|
-
|
|
Feb 16
2021
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
278,058
+50.0%
|
-
|
|
Feb 16
2021
|
Bruce Wendel Director |
BUY
Grant, award, or other acquisition
|
Direct |
347,572
+49.64%
|
-
|
|
Dec 22
2020
|
Bruce Wendel Director |
BUY
Open market or private purchase
|
Direct |
1,815
+15.41%
|
$14,520
$8.8 P/Share
|
|
Dec 22
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
47,978
-1.27%
|
$0
$0.4 P/Share
|
|
Dec 21
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
135,722
-1.17%
|
$0
$0.32 P/Share
|
|
Dec 18
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
50,000
-1.26%
|
$0
$0.3 P/Share
|
|
Dec 17
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
100,000
-1.24%
|
$0
$0.31 P/Share
|
|
Dec 16
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
50,000
-1.22%
|
$0
$0.3 P/Share
|